Pharmaceutical Patent Term Extension

March 27, 2019

A period of market exclusivity is critical for most novel pharmaceutical products and the duration of that exclusivity has a direct impact on the value of a pharmaceutical asset. There several forms of exclusivity that can apply to pharmaceutical products. This overview is a summary of one of them: the patent term adjustment.

Spotlight

Biolab Sanus Farmaceutica

Biolab is one of the 10 largest pharmaceutical companies in Brazil. The main characteristics about the trajectory is based on the commitment to offer health and quality of life to the Brazilian population. It is a market leader in Cardiology medicine prescriptions, vice-leader in the segment of Gynecology and acts with relevance in the areas of Dermatology, Orthopedics, Rheumatology and Pediatrics. With a portfolio of more than 100 products, Biolab has one of the most modern Research, Development and Innovation (R&D) Centers in Brazil and is growing as a result of partnerships with universities and national and international research laboratories, as well as commitment with actions of social responsibility and support to Brazilian culture.

OTHER WHITEPAPERS
news image

Characterization of Protein Aggregates and Other Particles in Biopharmaceuticals

whitePaper | July 8, 2022

Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.

Read More
news image

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More
news image

Infosys and Top Pharma Bring Digital Transformation to DrugManufacturing Data

whitePaper | April 1, 2022

In 2017, a top 20 global pharmaceutical company began a journey to digitally transform its pharmaceutical engineering and manufacturing capabilities by constructing a data integration and visualization platform, with strategic assistance and technical implementation provided by its partner Infosys.

Read More
news image

Understanding Net Pharmaceutical Expenditure Dynamics in Europe

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

Read More
news image

Blockchain technology in the pharmaceutical industry

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

Read More
news image

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Read More

Spotlight

Biolab Sanus Farmaceutica

Biolab is one of the 10 largest pharmaceutical companies in Brazil. The main characteristics about the trajectory is based on the commitment to offer health and quality of life to the Brazilian population. It is a market leader in Cardiology medicine prescriptions, vice-leader in the segment of Gynecology and acts with relevance in the areas of Dermatology, Orthopedics, Rheumatology and Pediatrics. With a portfolio of more than 100 products, Biolab has one of the most modern Research, Development and Innovation (R&D) Centers in Brazil and is growing as a result of partnerships with universities and national and international research laboratories, as well as commitment with actions of social responsibility and support to Brazilian culture.

Events